Conditions: Healthy
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 24
Healthy volunteers: yes

Brief summary:
This study evaluates a new formulation of LY900014, a drug that lowers blood sugar. It is administered by injection under the skin of the abdomen. The study will be conducted in healthy people to investigate how quickly and how much LY900014 is absorbed and the effect of different doses of LY900014 on blood sugar levels. Side effects and tolerability will be documented. The study will last for about 8 to 9 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

Detailed description:

Arms:
arm 1: Single dose of 7.5 U LY900014 administered subcutaneously (SC) in one to two of five periods. arm 2: Reference formulation. Single dose of Insulin Lispro administered SC in one to two of five periods. arm 3: Single dose of 15 U LY900014 administered subcutaneously (SC) in one to two of five periods. arm 4: Single dose of 30 U LY900014 administered subcutaneously (SC) in one to two of five periods.

Interventions: intervention 1: LY900014 intervention 2: Insulin Lispro (Humalog)
Intervention descriptions: intervention 1: Administered SC intervention 2: Administered SC

Protocol document: